Pfizer's Tanezumab receives almost unanimous rejection by FDA Adcom, page-15

$100 per share is only AUD $23 billion (USD $18 billion). Myokardia got sold to BMS for USD $13 billion late last year for a Phase 3 heart condition drug affecting 1 in 500 people vs OA around 1 in 10 people. BMS just submitted their NDA last week for it so yes they are ahead in terms of clinical development. $100 does seem crazy to think about today but it is not outside the realm of possibility since PPS has the potential to be the holy grail treatment for OA - “the last frontier for big diseases without a treatment”